FDA

FDA Advisers Find Replimune’s RP1 Trial Results Clinically Meaningful

The panel’s vote strengthens the case for accelerated approval by spotlighting an efficacy signal in a hard‑to‑treat group despite lingering agency doubts about the study’s reliability.